Medical Devices Company Investment Opportunity in İstanbul, Turkey

- We design medical products based on the experience and needs felt by the patients and medical professionals.

- Our vertigo (BPPV) treatment chair is substantially equivalent to legally marketed predicate devices and does not require approval of a pre-market approval application (PMA) according to FDA 510 (k) regulations.

- We would like to use part of the investment to manufacture a model with a smaller footprint and better cosmetics. The models are ready.

- USA is the market with the highest potential for our vertigo (BPPV) treatment device.

- We have an AI-based decision support system (DSS) as an accessory to vertigo (BPPV) treatment chair to aid physicians to diagnose the condition. But the addition of the AI system may require PMA.

- Company's main focus is on designing and production of ENT products.

- We manufacture and design our products in-house and the manufacturing capacity is 2 devices per month but can scale up quickly to 20 and even higher if needed.

- Promoters have put 3 years of research and development into the product designs.

- We have just received our CE certifications to start commercial sales, so no revenue yet.

- Products are tested and devices have been approved by Turkish Health Ministry authorities and are in the final stages of being offered for sale.

- The success of our device is proven in the field by clinical trials.

- The product has multiple national and international patent applications.

- Our main product has received three awards, one of them by the votes of 75,000 medical professionals.

- The product has been launched at two specialist medical congresses and has received approval from opinion leaders of the vestibular society.

- Promoters have more than 30 years of experience in this field.

- Company is debt-free and owned by 3 partners, two stakeholders have a 40% stake each and one minority stakeholder has a 20% stake in the company.

- Vertigo (BPPV) is a notoriously difficult illness to treat. Statistically, patients visit the hospital 7 times on average and it takes 70 months to get a cure.

- The misdiagnosis rate of BPPV in ER is as high as 80%. We have a robotic treatment system that simplifies diagnosis and treatment.

- The average diagnosis and treatment time for 32 clinical trial patients was 20 minutes. We had patients who visited the hospital 14 times with no success yet were cured in 20 minutes.

- BPPV affects 8% of the population but 1.6% of the whole population visits emergency rooms worldwide every year in every country for BPPV attacks.

Robotic repositioning chair for diagnosis and treatment of vertigo (BPPV) patients, AI-based decision support tool for diagnosis of BPPV, nasal interface for a new type of HFNC mask, medico-legal recording device for endoscopic video operations and no-surgery eustachian tube dysfunction diagnosis and treatment tool.

Physical assets include manufacturing equipment and other assets include 10 patent applications.

The company's HQ is located in a technopark, and we have a workshop of 600 square meters in Ankara for fabrication.

The project was initially funded by the Tubitak, (Governmental Research organization of Turkiye) in Teydep 1511 project where high-priority projects were funded. The industrial version of the product has been funded by the partners.

Currently, the business is being funded by partners. The company has no debts of any sort.